IOVA News and Press, Iovance Biotherapeutics Inc. From 11/08/23

2023-11-08 13:03:43 ET On a brutal day for biotech stocks, Iovance Biotherapeutics (NASDAQ: IOVA) is defying the broader trend across the space. Specifically, the adoptive cell therapy company's shares were up by 7.75% on heavy volume as of 11:49 a.m. ET Wednesday. Meanwhile, th...

2023-11-07 23:22:12 ET Iovance Biotherapeutics, Inc. (IOVA) Q3 2023 Earnings Conference Call November 07, 2023, 16:30 ET Company Participants Sara Pellegrino - VP, IR & Public Relations Frederick Vogt - Interim CEO, President, General Counsel & Corporate ...

2023-11-07 16:14:14 ET More on Iovance Biotherapeutics Iovance Biotherapeutics: Testing Shareholders' Patience Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Fine...

FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023 Positive Regulatory Feedback Supports Lifileucel Regulatory Submissions in Europe and Canada in 2024 ...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Iovance Biotherapeutics Inc. (IOVA) is expected to report $-0.46 for Q3 2023

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and ...

2023-10-22 09:12:19 ET Summary Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on the belief that adoptive cell therapy can effectively fight solid tumors while avoiding side effects...

2023-10-21 03:29:32 ET Summary Cathie Wood and ARK Investment Management have abandoned their "soft landing" theory and are actively preparing for other scenarios. ARK now expects an "economic landing stronger than soft", while facing more than a billion in net fund outflows since...

2023-10-19 14:35:36 ET Summary Iovance Biotherapeutics' lifileucel, a tumor infiltrating lymphocyte product, is under FDA review for the treatment of advanced melanoma. The FDA decision on the biologics license application for lifileucel has been delayed until February 24, 2024. ...